GRIN Therapeutics Expands Phase 3 Beeline Trial to Europe for Rare Neurodevelopmental Disorder Treatment
Key Insights
GRIN Therapeutics (search) initiated its pivotal Phase 3 Beeline study in Europe, expanding the global registrational program for investigational radiprodil in GRIN-related neurodevelopmental disorder (search).
The trial builds on promising Phase 1b/2a Honeycomb study results showing an 86% median reduction in seizure frequency among patients with countable motor seizures (search).
Radiprodil targets NMDA receptor overactivation and has received multiple regulatory designations including FDA Breakthrough Therapy and EMA Priority Medicines status.
GRIN Therapeutics (search) announced the initiation of its pivotal Phase 3 Beeline study in Europe, marking a significant milestone in the global development program for investigational radiprodil in GRIN-related neurodevelopmental disorder (search) (GRIN-NDD (search)). The expansion augments existing enrollment sites in the United States and United Kingdom, bringing the company closer to potentially delivering the first targeted, disease-modifying therapy for this rare condition.
The Phase 3 Beeline trial represents a global, registrational study designed to evaluate the efficacy and safety of radiprodil, a selective negative allosteric modulator of the NMDA receptor GluN2B subunit (search), in patients with GRIN-NDD (search) caused by gain-of-function variants. By targeting the underlying biology of NMDA receptor overactivation, radiprodil has the potential to address core aspects of the disease, including seizures (search), behavioral manifestations, and functional outcomes.
"This is an exciting and meaningful milestone for GRIN Therapeutics (search) and, more importantly, for the GRIN-NDD (search) community," said Bruce Leuchter, MD, President and Chief Executive Officer of GRIN Therapeutics. "Expanding the Beeline study into Europe brings us closer to delivering what we hope will be the first targeted, disease-modifying therapy for patients living with this complex and life-altering condition."
Promising Early-Stage Results Drive Phase 3 Advancement
The Beeline trial builds on encouraging results from the open-label Phase 1b/2a Honeycomb study, which demonstrated clinical activity and tolerability of radiprodil in patients with GRIN-NDD (search) caused by gain-of-function variants. In that study, patients with countable motor seizures (search) experienced a median reduction of 86% in seizure frequency. Additionally, clinicians and caregivers observed signs of a favorable effect on clinical outcomes regardless of the occurrence of seizures, as measured by Clinician and Caregiver Global Impressions of Change.
These compelling data supported the granting of Priority Medicines (PRIME) designation by the European Medicines Agency (search). The Honeycomb data, combined with insights from patients, caregivers, and investigators, informed the design of the Phase 3 program, including a disease-specific endpoint designed to capture behavioral symptoms that clinicians and caregivers consider meaningful.
European Expansion Accelerates Global Access
The initiation of sites in Belgium, France, Germany, Italy, Poland, the Netherlands, Slovenia, and Spain represents the next step in the global expansion of the Beeline trial. European activation includes both experienced centers that participated in earlier studies and new clinical sites across multiple countries, supporting efficient study execution and broader patient access. Further EU countries are anticipated to come online in September 2026.
The addition of European sites is expected to accelerate progress of the Phase 3 study while expanding access for European patients and families seeking new treatment options. The Phase 3 program includes a cohort that enables enrollment of patients with behavioral symptoms, not requiring countable motor seizures (search), broadening the potential patient population.
Regulatory Recognition and Broader Development Pipeline
Radiprodil has received significant regulatory recognition for its therapeutic potential. The investigational drug has been awarded Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations by the U.S. Food and Drug Administration (search), as well as Priority Medicines (PRIME) designation by the European Medicines Agency (search) and a positive opinion for orphan designation from the EMA Committee for Medicinal Products for Human Use.
Beyond GRIN-NDD (search), radiprodil is also being assessed for the treatment of tuberous sclerosis complex (search) (TSC) and focal cortical dysplasia (FCD) type II, two disorders associated with NMDA receptor overexpression. The Astroscape trial is an ongoing, open-label Phase 1b/2a clinical trial assessing the safety, tolerability, pharmacokinetics, and potential efficacy of radiprodil in patients with TSC or FCD type II.
Company Background and Strategic Support
GRIN Therapeutics (search) is dedicated to the research and development of precision therapeutics for neurodevelopmental disorders. In late 2024, the company reported promising topline data from the Honeycomb Trial, leading to the decision to advance to the global pivotal Phase 3 Beeline trial. GRIN Therapeutics is an affiliate of Neurvati Neurosciences (search), a portfolio company of Blackstone Life Sciences (search), which currently has more than $17 billion in assets under management.
Families seeking more information about the trial can reach out to international groups like GRIN Europe and CureGRIN, or their national advocacy groups for additional resources and support.